Tosilizumab

Antibodi monoklonal
Jenis	Whole antibody
Sumber	Templat:Infobox drug/mab source
Target	Reseptor IL-6
Data klinis
Nama dagang	Actemra, Roactemra
Biosimilar	tocilizumab-aazg,[1][2] tocilizumab-bavi,[3][4] Tofidence,[3][4][5][6][7] Tyenne[1][8]
AHFS/Drugs.com	monograph
MedlinePlus	a611004
License data	US DailyMed: Tocilizumab
Kategori kehamilan	AU: C [9]
Rute pemberian	Intravena, subkutan
Kode ATC	L04AC07 (WHO)
Status hukum
Status hukum	AU: S4 (Prescription only) [9][10] CA: ℞-only [11] US: ℞-only [12] and Emergency Use Authorization[13] EU: Rx-only [6][8][14][15][16] ℞ (Hanya resep)
Data farmakokinetika
Waktu paruh eliminasi	8–14 hari selama kondisi stabil (tergantung pada konsentrasi)
Pengenal
Nomor CAS	375823-41-9 N
DrugBank	DB06273 Y
ChemSpider	none
UNII	I031V2H011
KEGG	D02596 Y
ChEMBL	ChEMBL1237022 N
Data sifat kimia dan fisik
Rumus	C6428H9976N1720O2018S42
Massa molar	144.987,06 g·mol−1
NY (what is this?)  (verify)

Tosilizumab, dijual dengan nama merek Actemra, adalah sebuah obat imunosupresif, yang dipakai untuk pengobatan artritis reumatoid dan artritis idiopatik remaja sistemik, sebuah bentuk artritis berat pada anak-anak. Tocilizumab dikembangkan bersama oleh Universitas Osaka dan Chugai, dan dilisensikan pada 2003 oleh Hoffmann-La Roche.^[17]

Tocilizumab diberikan pengaturan pemakaian darurat untuk pengobatan COVID-19 di Amerika Serikat pada Juni 2021.^[18]

Referensi

Pranala luar

• Nomor uji klinis NCT00109408 for "A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis" di ClinicalTrials.gov
• Nomor uji klinis NCT00106535 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)" di ClinicalTrials.gov
• Nomor uji klinis NCT00106548 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis" di ClinicalTrials.gov
• Nomor uji klinis NCT00106574 for "A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis" di ClinicalTrials.gov
• Nomor uji klinis NCT00106522 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy" di ClinicalTrials.gov
• Nomor uji klinis NCT01331837 for "A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors" di ClinicalTrials.gov
• Nomor uji klinis NCT00988221 for "A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis" di ClinicalTrials.gov
• Nomor uji klinis NCT00642460 for "A Study of Roactemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)" di ClinicalTrials.gov

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

• l
• b
• s